PE20231096A1 - Polimorfos de un inhibidor de ssao - Google Patents

Polimorfos de un inhibidor de ssao

Info

Publication number
PE20231096A1
PE20231096A1 PE2023000721A PE2023000721A PE20231096A1 PE 20231096 A1 PE20231096 A1 PE 20231096A1 PE 2023000721 A PE2023000721 A PE 2023000721A PE 2023000721 A PE2023000721 A PE 2023000721A PE 20231096 A1 PE20231096 A1 PE 20231096A1
Authority
PE
Peru
Prior art keywords
polymorph
present
polymorphs
refers
ssao inhibitor
Prior art date
Application number
PE2023000721A
Other languages
English (en)
Inventor
David Michael Remick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20231096A1 publication Critical patent/PE20231096A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Refiere a un polimorfo de (2E)-3-fluoro-2-({[2-(4-metoxipiperidin-1-il)pirimidin-5- il]oxi}metil)prop-2-en-1-aminio 4-metilbencenosulfonato, que se caracteriza por presentar un patron de difraccion de rayos X (XRPD) con picos en angulos 2-theta de 8.3±0.2, 13.7±0.2, 18.0±0.2, 18.3±0.2 y 25.5±0.2 grados, y un inicio endotermico de 123°C a 174°C determinado por calorimetria diferencial de barrido (DSC). Tambien, la presente reivindica una composicion farmaceutica a base del presente polimorfo y sustancialmente libre de otras formas polimorficas; ademas refiere a metodos para preparacion del polimorfo y para el tratamiento de trastornos hepaticos como la esteatopatitis no alcoholica (NASH).
PE2023000721A 2020-08-25 2021-08-24 Polimorfos de un inhibidor de ssao PE20231096A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070147P 2020-08-25 2020-08-25
PCT/US2021/047363 WO2022046779A1 (en) 2020-08-25 2021-08-24 Polymorphs of an ssao inhibitor

Publications (1)

Publication Number Publication Date
PE20231096A1 true PE20231096A1 (es) 2023-07-18

Family

ID=80355663

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000721A PE20231096A1 (es) 2020-08-25 2021-08-24 Polimorfos de un inhibidor de ssao

Country Status (14)

Country Link
US (1) US11820754B2 (es)
EP (1) EP4204405A4 (es)
JP (1) JP2023539639A (es)
KR (1) KR20230058112A (es)
CN (1) CN116615416A (es)
AU (1) AU2021332217A1 (es)
CA (1) CA3193057A1 (es)
CL (1) CL2023000537A1 (es)
CO (1) CO2023002085A2 (es)
IL (1) IL300853A (es)
MX (1) MX2023002308A (es)
PE (1) PE20231096A1 (es)
TW (1) TW202227406A (es)
WO (1) WO2022046779A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300853A (en) 2020-08-25 2023-04-01 Lilly Co Eli SSAO inhibitor polymorphs

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
WO2008123469A1 (ja) 2007-03-30 2008-10-16 Japan Tobacco Inc. ６員環アミド化合物およびその用途
DK2170403T3 (da) 2007-06-27 2014-06-16 Quark Pharmaceuticals Inc Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
AU2008280784A1 (en) 2007-07-20 2009-01-29 Merck Frosst Canada Ltd Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
WO2010084944A1 (ja) 2009-01-22 2010-07-29 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
US20110014558A1 (en) 2009-07-15 2011-01-20 Kabushiki Kaisha Toshiba Developing agent and method for producing the same
JP2011136942A (ja) 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
HUE028394T2 (en) 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidin Compound
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
SG10201707020TA (en) 2012-05-02 2017-10-30 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof
JP6322202B2 (ja) 2012-11-16 2018-05-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピロリジンｇｐｒ４０修飾因子
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
US8962641B2 (en) 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
WO2014184104A1 (en) 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
AU2014337064B2 (en) 2013-10-18 2019-03-14 Celgene Quanticel Research, Inc. Bromodomain inhibitors
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
BR112018069789A2 (pt) 2016-03-28 2019-01-29 Intercept Pharmaceuticals Inc medicamento obtido pela combinação do agonista de fxr e arb
MX2021015783A (es) 2016-03-31 2022-12-09 Genfit Metodos de tratamiento de enfermedades colestaticas.
SG10202011660RA (en) 2016-05-25 2020-12-30 Akarna Therapeutics Ltd Combination therapies with farnesoid x receptor (fxr) modulators
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
AU2017344882A1 (en) 2016-10-19 2019-03-28 Boehringer Ingelheim International Gmbh Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
CN108883185B (zh) 2016-12-06 2021-10-08 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
CN108341752B (zh) 2017-01-21 2022-12-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
JP2020508316A (ja) 2017-02-21 2020-03-19 ジェンフィＧｅｎｆｉｔ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
CA3054103A1 (en) 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CA3057940A1 (en) 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
CN109251166B (zh) 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2019023245A1 (en) 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES
US20200248261A1 (en) 2017-08-25 2020-08-06 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
EP3684954A1 (en) 2017-09-18 2020-07-29 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
WO2019094777A1 (en) 2017-11-13 2019-05-16 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
KR20210002573A (ko) 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
WO2019241751A1 (en) 2018-06-15 2019-12-19 Metacrine, Inc. Ssao inhibitors and uses thereof
AU2018438845A1 (en) 2018-08-30 2021-04-01 Terns Pharmaceuticals, Inc. Treating liver disorders
US20220047553A1 (en) 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020086747A2 (en) 2018-10-24 2020-04-30 Metacrine, Inc. Ssao inhibitors and uses thereof
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
AU2020319052A1 (en) 2019-07-23 2022-01-27 Novartis Ag Combination treatment of liver diseases using FXR agonists
CA3142904A1 (en) 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
AU2021241646A1 (en) 2020-03-25 2022-11-24 Terns, Inc. Treatment of respiratory disorders
KR20230023642A (ko) 2020-05-13 2023-02-17 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
KR20230024277A (ko) 2020-05-13 2023-02-20 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
IL300853A (en) 2020-08-25 2023-04-01 Lilly Co Eli SSAO inhibitor polymorphs
US20230241071A1 (en) 2021-11-11 2023-08-03 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CA3238102A1 (en) 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor

Also Published As

Publication number Publication date
KR20230058112A (ko) 2023-05-02
CN116615416A (zh) 2023-08-18
MX2023002308A (es) 2023-07-11
JP2023539639A (ja) 2023-09-15
WO2022046779A1 (en) 2022-03-03
CL2023000537A1 (es) 2023-12-15
EP4204405A4 (en) 2024-05-29
EP4204405A1 (en) 2023-07-05
CA3193057A1 (en) 2022-03-03
US11820754B2 (en) 2023-11-21
TW202227406A (zh) 2022-07-16
US20220089563A1 (en) 2022-03-24
AU2021332217A1 (en) 2023-05-11
IL300853A (en) 2023-04-01
CO2023002085A2 (es) 2023-03-07

Similar Documents

Publication Publication Date Title
RU2008127312A (ru) Мезилатное пролекарство леводопы, его композиции и применение
TW407144B (en) Arylalkylamine calcilytic compounds and pharmaceutical compositions containing these compounds
US7154001B2 (en) Formate salt of O-desmethyl-venlafaxine
PE20231096A1 (es) Polimorfos de un inhibidor de ssao
RU2018145296A (ru) Простое эфирное производное никотинилового спирта, получение и фармацевтическая композиция и применения
CL2021002961A1 (es) Un procedimiento para la fabricación de ácido(2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a, 5,10,10a-octahidrobenzo[g]quinolin-6-il)oxi) tetrahidro-2h-piran-2-carboxílico.
CL2021002775A1 (es) Un procedimiento para la fabricación de ácido(2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a,5, 10,10a-octahidrobenzo[g]quinolin-6-il)oxi)tetrahidro-2h-piran-2-acido carboxílico y sus intermedios.
US8178527B2 (en) Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US7208520B2 (en) Crystals of hydroxynorephedrine derivative
JP2010189410A (ja) 新規アミノベンゾフェノン
US20140018325A1 (en) Hiv protease inhibitors
TW200304815A (en) NK1 antagonists
EP2613775A1 (en) Novel n-hydroxy-benzamides for the treatment of cancer
US5756475A (en) Isoprene derivatives
HU229077B1 (hu) 2-Aril-propionsav-származékok és az azokat tartalmazó gyógyászati készítmények
JP4083221B2 (ja) アミノテトラリン誘導体及び組成物並びにその使用方法
Zhao et al. Design, synthesis and anti-proliferative effects in tumor cells of new combretastatin A-4 analogs
D'hooghe et al. A new approach towards 2-amino-1-aryloxy-3-methoxypropanes from 1-arylmethyl-2-(bromomethyl) aziridines
AU2013354133B2 (en) Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
CN109134432B (zh) 氘代抗抑郁药物
TW581754B (en) 2-methylpropionic acid derivatives and pharmaceutical compositions comprising the same
US20150374709A1 (en) Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
JPWO2011040509A1 (ja) ２，３−ジヒドロ−１ｈ−インデン−２−イルウレア誘導体及びその医薬用途
US20070191627A1 (en) Stilbene derivatives and their use in medicaments
ES2349066T3 (es) Compuestos de piridilmetilbiciclocarboxamida sustituida.